VADUZ, Liechtenstein, Aug. 21, 2026 /PRNewswire/ -- FDA Approval of RefluxStop$(R)$ - Strategic Preparation Sets the Stage for Success

Significant events in the second quarter of 2026

   -- RefluxStop(R) sales increased by more than 60% compared with the 
      prior-year period, reflecting continued commercial growth across key 
      European markets 
 
   -- Largest independent RefluxStop(R) study to date published in Nature's 
      Scientific Reports, reporting mid- to long-term safety outcomes in 602 
      patients across 22 centers in six European countries, with serious safety 
      events and reoperations below 2% 
 
   -- Clinical, health-economic and reimbursement evidence further strengthened, 
      including new Italian cost-effectiveness data and the addition of a 
      seventh InEK-reporting hospital in Germany supporting the reimbursement 
      pathway 

Significant events after the end of the period

   -- FDA PMA approval secured for RefluxStop(R), opening the U.S. market and 
      enabling the start of U.S. commercial launch activities 
 
   -- U.S. market entry underway, with expansion of the U.S. organization and 
      establishment of logistics and distribution infrastructure 
 
   -- European market presence continued to expand, including the 20th Center 
      of Excellence in Spain at MD Anderson Madrid and new Centers in 
      Switzerland and the UK, bringing the European network to more than 60 
      Centers of Excellence 

Financial summary second quarter

   -- Net sales increased by 66% to TEUR 717 (433). 
 
   -- Adjusted gross margin amounted to 94% (90%). 
 
   -- Operating loss $(EBIT)$ decreased to TEUR 4,200 (4,525). 
 
   -- Loss after tax amounted to TEUR 3,987 (5,448). 
 
   -- Basic and diluted loss per Class A share amounted to EUR 0.06 (0.08). 
 
   -- Cash and cash equivalents as at the end of the period of MEUR 41.7. 

Financial summary first six months

   -- Net sales increased 34% to TEUR 1,574 (1,178). 
 
   -- Adjusted gross margin amounted to 94% (94%). 
 
   -- Operating loss (EBIT) decreased to TEUR 8,058 (8,698). 
 
   -- Loss after tax amounted to TEUR 8,267 (8,212). 
 
   -- Basic and diluted loss per Class A share amounted to EUR 0.12 (0.12). 

Telephone conference

Implantica will hold a teleconference on 21 August 2026 at 15:00 (CEST) with Peter Forsell (CEO), Andreas Öhrnberg (CFO), and Nicole Pehrsson (Chief Corporate Affairs Officer). Please see the dial-in details below to join the conference:

Webcast

If you wish to participate via webcast, please use the following link:

https://implantica.events.inderes.com/q2-report-2026

Dial-in

Dial-in numbers to the teleconference will be received by registering on the link below. After the registration, you will be provided phone numbers and a conference ID to access the conference.

https://events.inderes.com/implantica/q2-report-2026/dial-in

For further information, please contact:

Nicole Pehrsson, Chief Corporate Affairs Officer

Telephone (CH): +41 (0)43 505 20 57

nicole.pehrsson@implantica.com

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.

The company's Certified Adviser is FNCA Sweden AB, info@fnca.se

This information is information that Implantica AG is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 2026-08-21 08:00 CEST.

About Implantica

Implantica is a medtech company focused on bringing advanced implantable technologies into the body designed to improve patient outcomes and quality of life. The company's lead product, RefluxStop(R), is an FDA approved and CE-marked implant for the treatment of gastroesophageal reflux disease (GERD) with the potential to transform the standard of care in anti-reflux surgery, supported by strong long-term clinical outcomes.

In addition to RefluxStop(R), Implantica has developed a broad, patent-protected product pipeline partly incorporating two platform technologies: an eHealth platform designed to enable communication with and remote monitoring and control of implants inside the body, and a wireless energizing platform designed to wirelessly power implantable devices through intact skin. These investigational devices are intended to facilitate remote changes to treatment, potentially saving cost for society.

Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/implantica/r/implantica-publishes-interim-report-january---june-2026--q2-, c4386079

The following files are available for download:

 
https://mb.cision.com/Main/19732/4386079/4  Implantica Q2 2026 ENG 
227684.pdf 
https://mb.cision.com/Public/19732/4386079  Implantica publishes Interim 
/8f9f7fd01620b71b.pdf                       Report Jan - Jun 2026 Q2 
 

View original content:https://www.prnewswire.com/news-releases/implantica-publishes-interim-report-january--june-2026-q2-302857152.html

SOURCE Implantica